Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: 2nd long-term results of NRG/RTOG 9402 - reporting with a EORTC Study

Andrew B. Lassman, MD

NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical resection (SR) for newly oligometastatic breast cancer

Steven J. Chmura, MD

Effects of the WRITE symptoms interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG Oncology/GOG Study (GOG-0259)

Heidi S. Donovan, PhD, RN

Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002

Sue S. Yom, MD, PhD

Prostate cancer therapy personalization via multimodal deep learning

Osama Mohamad, MD, PhD

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010

Theodore S. Hong, MD